AN ASSAY FOR CIRCULATING ANTIBODIES TO A MAJOR ETIOLOGIC VIRUS OF HUMAN NON-A, NON-B-HEPATITIS
AN ASSAY FOR CIRCULATING ANTIBODIES TO A MAJOR ETIOLOGIC VIRUS OF HUMAN NON-A, NON-B-HEPATITIS
复制标题
DOI：
10.1126/science.2496467
复制
发表时间：
1989-04-21
期刊：
影响因子：
56.9
通讯作者：
HOUGHTON, M
中科院分区：
文献类型：
--
作者：
KUO, G;CHOO, QL;HOUGHTON, M
已经开发了一种针对血源性非甲非乙型肝炎（NANBH）病毒的特异性测定，其中使用在丙型肝炎病毒（HCV）的重组酵母克隆中合成的多肽来捕获循环病毒抗体。HCV抗体在7个人血清中的6个中检测到，这些人血清先前显示将NANBH传播给黑猩猩。对美国10例导致慢性NANBH的输血的分析显示，其中9例至少有一名阳性献血者，所有10名受血者在患病期间都发生了血清转化。来自意大利和日本的慢性输血后NANBH（PT-NANBH）患者中约有80%存在循环HCV抗体;在急性缓解感染中观察到的频率要低得多（15%）。此外，来自美国的NANBH患者中有58%没有可识别的肠胃外接触病毒的来源，也对HCV抗体呈阳性。这些数据表明，HCV是全世界NANBH的主要原因。
A specific assay has been developed for a blood-borne non-A, non-B hepatitis (NANBH) virus in which a polypeptide synthesized in recombinant yeast clones of the hepatitis C virus (HCV) is used to capture circulating viral antibodies. HCV antibodies were detected in six of seven human sera that were shown previously to transmit NANBH to chimpanzees. Assays of ten blood transfusions in the United states that resulted in chronic NANBH revealed that there was at least one positive blood donor in nine of these cases and that all ten recipients seroconverted during their illnesses. About 80 percent of chronic, post-transfusion NANBH (PT-NANBH) patients from Italy and Japan had circulating HCV antibody; a much lower frequency (15 percent) was observed in acute, resolving infections. In addition, 58 percent of NANBH patients from the United States with no identifiable source of parenteral exposure to the virus were also positive for HCV antibody. These data indicate that HCV is a major cause of NANBH throughout the world.